BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21922393)

  • 21. Update on clinical role of tamoxifen.
    Benson JR; Pitsinis V
    Curr Opin Obstet Gynecol; 2003 Feb; 15(1):13-23. PubMed ID: 12544497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
    Mackey JR
    J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
    [No Abstract]   [Full Text] [Related]  

  • 23. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen deprivation therapy and colon cancer risk in breast cancer patients.
    Malaka DO; Olopade OI
    Breast J; 2010; 16(1):110-2. PubMed ID: 19929891
    [No Abstract]   [Full Text] [Related]  

  • 27. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of breast cancer in very young women.
    Freedman RA; Partridge AH
    Breast; 2013 Aug; 22 Suppl 2():S176-9. PubMed ID: 24074783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
    Hayes DF
    J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant hormonal therapy.
    Tamaki Y; Miyoshi Y; Noguchi S
    Breast Cancer; 2002; 9(3):185-9. PubMed ID: 12185327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The continued evidence from overviews: what is the clinical utility?
    Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
    Breast; 2013 Aug; 22 Suppl 2():S8-11. PubMed ID: 24074798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.
    Hudis CA; Dang CT
    Breast Dis; 2004; 21():3-13. PubMed ID: 15687717
    [No Abstract]   [Full Text] [Related]  

  • 34. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer.
    Kolarova I; Vanasek J; Odrazka K; Melichar B; Ryska A; Petera J; Vosmik M; Dolezel M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):285-292. PubMed ID: 31831888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From genome to bedside: are we lost in translation?
    Hayes DF
    Breast; 2013 Aug; 22 Suppl 2():S22-6. PubMed ID: 24074786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine therapy of breast cancer.
    Goldhirsch A; Colleoni M; Gelber RD
    Ann Oncol; 2002; 13 Suppl 4():61-8. PubMed ID: 12401668
    [No Abstract]   [Full Text] [Related]  

  • 38. Patients with triple negative breast cancer: is there an optimal adjuvant treatment?
    Burstein HJ
    Breast; 2013 Aug; 22 Suppl 2():S147-8. PubMed ID: 24074776
    [No Abstract]   [Full Text] [Related]  

  • 39. Who benefits from hormone therapy?
    Toi M; Iino Y
    Breast Cancer; 2006; 13(2):117-22. PubMed ID: 16755104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management recommendations for adjuvant systemic breast cancer therapy.
    Perez EA
    Breast Dis; 2004; 21():15-21. PubMed ID: 15687718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.